-
Mashup Score: 3Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation - 24 day(s) ago
Dysregulated epigenetic programs that restrict differentiation, reactivate fetal genes, and confer phenotypic plasticity are critical to colorectal cancer (CRC) development. By screening a small molecule library targeting epigenetic regulators using our dual reporter system, we found that inhibiting histone deacetylase (HDAC) 1/2 promotes CRC differentiation and anti-tumor activity. Comprehensive biochemical, chemical, and genetic experiments revealed that on-target blockade of the HDAC1/2 catalytic domain mediated the differentiated phenotype. Unbiased profiling of histone posttranslational modifications induced by HDAC1/2 inhibition nominated acetylation of specific histone lysine residues as potential regulators of differentiation. Genome-wide assessment of implicated marks indicated that H3K27ac gains at HDAC1/2-bound regions associated with open chromatin and upregulation of differentiation genes upon HDAC1/2 inhibition. Disrupting H3K27ac by degrading acetyltransferase EP300 resc
Source: www.biorxiv.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6America's Best Prostate Cancer Oncologists 2024 - 3 month(s) ago
To spotlight the country’s top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America’s Best Prostate Cancer Oncologists & Surgeons.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet-
Thrilled to see my good friend @BrunoBastosMD being recognized on this list! Well deserved!!! #BestProstateCancerDocs https://t.co/WYsjSPu5ff
-
-
Mashup Score: 5America's Best Prostate Cancer Oncologists 2024 - 7 month(s) ago
To spotlight the country’s top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America’s Best Prostate Cancer Oncologists & Surgeons.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet-
Thrilled to see my good friend @BrunoBastosMD being recognized on this list! Well deserved!!! #BestProstateCancerDocs https://t.co/WYsjSPu5ff
-
-
Mashup Score: 5America's Best Prostate Cancer Oncologists 2024 - 7 month(s) ago
To spotlight the country’s top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America’s Best Prostate Cancer Oncologists & Surgeons.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet-
Thrilled to see my good friend @BrunoBastosMD being recognized on this list! Well deserved!!! #BestProstateCancerDocs https://t.co/WYsjSPu5ff
-
-
Mashup Score: 5America's Best Prostate Cancer Oncologists 2024 - 7 month(s) ago
To spotlight the country’s top prostate cancer specialists, Newsweek is partnering with Statista for the first annual ranking of America’s Best Prostate Cancer Oncologists & Surgeons.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet-
Thrilled to see my good friend @BrunoBastosMD being recognized on this list! Well deserved!!! #BestProstateCancerDocs https://t.co/WYsjSPu5ff
-
-
Mashup Score: 9Research Laboratory Job: Scientist II at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA - 9 month(s) ago
Scientist II job
Source: careers.dana-farber.orgCategories: General Medicine News, Hem/OncsTweet-
RT @LabSethi: Come join our group! Please share with those interested. https://t.co/Ggv2cWsjQV https://t.co/SPQy1T3ewV
-
-
Mashup Score: 14
Cells carrying a monoallelic germline BRCA2 mutation can bypass Knudson’s “two-hit” requirement to initiate tumorigenesis when the glycolytic metabolite methylglyoxal transiently disables BRCA2 function. Metabolic bypass of tumor suppressor activity may link metabolic reprogramming, metabolic disorders, or diet to early steps in carcinogenesis.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet-
Very interesting paper that makes me think differently about how monoallelic loss of #BRCA2 can lead to #PancreaticCancer. https://t.co/wOr0R4UGcs
-
-
Mashup Score: 4Rough Sleepers: Dr. Jim O'Connell's urgent mission to bring healing to homeless people - 10 month(s) ago
Rough Sleepers: Dr. Jim O’Connell’s urgent mission to bring healing to homeless people
Source: www.amazon.comCategories: General Medicine News, Hem/OncsTweet-
Loved "Rough Sleepers", an inspiring #book about a team of healthcare workers devoted to caring for the #homeless. Incredibly challenging work. The book's message is that no matter who you are taking care of, medicine is always about relationships. @BHCHP https://t.co/hKAc24zYKf
-
-
Mashup Score: 33RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer - 11 month(s) ago
Abstract. Purpose: ERBB2 amplified colorectal cancer (CRC) is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. CRC cohorts with genomic profiling were used to identify ERBB2 amplified cases (Dana-Farber, n = 47/2,729 [1.7%]; FMI, n = 1857/49,839 [3.7%]). Outcomes of patients receiving HER2-directed therapies are reported (Dana-Farber, n = 9; Flatiron Health-Foundation Medicine clinicogenomic database, FH-FMI CGDB, n = 38). Multi-site HER2 immunohistochemistry and genomic profiling were performed to understand HER2 intratumoral and interlesional heterogeneity. The impact of concurrent RAS co-mutations on the effectiveness of HER2-directed therapies were studied in isogenic CRC cell lines and xenografts. Results: ERBB2 amplifications are enriched in left-sided CRC. 20% of ERBB2 amplified CRCs have co-occurring oncogenic RAS/RAF alterations. While RA
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
In this collaboration with Harsh Singh, @LabSethi, @JLHornick we examined mechanisms of resistance and sensitivity to targeted therapy in #HER2 amplified #ColorectalCancer. https://t.co/V0ngfsVYFu @CCR_AACR
-
-
Mashup Score: 9A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | NEJM - 11 month(s) ago
Original Article from The New England Journal of Medicine — A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Surprising result! A thyroid hormone receptor β (THR-β) agonist appears effective in improving #NASH. Decreased THR-β activation promotes NASH by "reducing mitochondrial function and β-oxidation of fatty acids" which ultimately leads to fibrosis. https://t.co/uDFoY6XLPu
-
RT @LabSethi: https://t.co/cROuPhuS8E. Aberrations in epigenetic regulation prevent cellular differentiation and endow plasticity to cancer…